CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with Type 2 diabetes

Diabetes Care

Volumn 39, Issue 11, 2016, Pages 1902-1908

  Dawed, Adem Y ^a   Donnelly, Louise ^a   Tavendale, Roger ^a   Carr, Fiona ^a   Leese, Graham ^a   Palmer, Colin N A ^a   Pearson, Ewan R ^a   Zhou, Kaixin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CYP2C8 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; SLCO1B1 PROTEIN, HUMAN;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYP2C8 GENE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFORMED CONSENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SCOTSMAN; SIDE EFFECT; SLCO1B1 GENE; TREATMENT RESPONSE; WEIGHT GAIN; AGED; CAUCASIAN; DIABETES MELLITUS, TYPE 2; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHARMACOGENETICS; SCOTLAND; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; CYTOCHROME P-450 CYP2C8; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCOTLAND; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84994335487     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2464     Document Type: Article

References (35)

1. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356: 2457-2471
3. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135
4. Levin D, Bell S, Sund R, et al.; Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia 2015;58:493-504
5. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis. Diabetes Care 2010;33: 1859-1864
6. Kahn SE, Haffner SM, HeiseMA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
7. Bailey CJ. Safety of antidiabetes medications: an update. Clin Pharmacol Ther 2015;98:185-195
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-175
10. Izumi R, Hurt J, Maki KC, Bell M, Zavras AI, McCamishM. Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapy. Diabetes Technol Ther 2007;9:553-561
11. Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:453-460
12. Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: A meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 2005;314:533-541
13. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999;48:424-432
14. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44-51
15. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000;28:772-780
16. Baba S. Pioglitazone: A review of Japanese clinical studies. Curr Med Res Opin 2001;17: 166-189
17. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-414
18. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311: 228-236
19. Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK. Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J 2009; 9:283-290
20. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics 2008;3:7-16
21. Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006;80:657-667
22. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8∗3 allele have opposite effects on the pharmacokinetics of pioglitazone.DrugMetabDispos 2008;36:73-80
23. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008;65:78-86
24. Morris AD, Boyle DI, MacAlpine R, et al.; DARTS/MEMO Collaboration. The Diabetes Audit and Research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. BMJ 1997;315:524-528
25. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607
26. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575
27. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002;21:35-50
28. Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;67:43-52
29. Miyazaki Y, Filippis ED, Bajaj M, et al. Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: A practical approach for the primary care physician. 2005. Br J Diabetes Vasc Dis 2005;5:28-35
30. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
31. Stage TB, Christensen MM, Feddersen S, Beck-Nielsen H, Brøsen K. The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARg on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics 2013;23:219-227
32. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 2001;121:19-25
33. Christensen MM, Pedersen RS, Stage TB, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics 2013;23:526-534
34. Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013;93:186-194
35. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010;20:38-44